---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008492"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:34:42.489293+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma Q1 2022: $256.2M cash runways into 2H2024; three Phase 1b data readouts in 1H2023

## Summary
- Cash and investments $256.2M as of March 31, 2022; expected to fund operations into 2H2024.
- R&D expenses $16.8M (up $5.1M YoY) driven by advancing ORIC-533, -114, -944; ORIC-101 discontinued.
- G&A expenses $6.4M (up $1.6M YoY) due to higher personnel costs.
- Three Phase 1b trials (ORIC-533 in multiple myeloma; ORIC-114 in EGFR/HER2; ORIC-944 in prostate) targeting initial data in 1H2023.
- PLK4 inhibitor program in lead optimization for TRIM37-amplified breast cancers.

## SEC filing metadata
- accession: 0000950170-22-008492
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/0000950170-22-008492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/oric-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008492
- JSON: https://secwatch.observer/filing/0000950170-22-008492.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008492.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.